Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2). Narcolepsy type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback